Your session is about to expire
← Back to Search
Antiviral
ASC10 for COVID-19
Phase 1
Waitlist Available
Research Sponsored by Ascletis Pharmaceuticals Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from day 1 to study completion, up to 32 days
Awards & highlights
Study Summary
This trial will test a new drug to see if it is safe, effective and how it works in people with mild-moderate COVID-19.
Eligible Conditions
- COVID-19
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from day 1 to study completion, up to 32 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 1 to study completion, up to 32 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Therapeutic procedure
PK parameters for ASC10, GLC01-700 (molnupiravir) and ASC10-A in plasma as AUC0-12h
Secondary outcome measures
Time (days) to sustained resolution of all targeted COVID-19 signs/symptoms
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: ASC10Experimental Treatment1 Intervention
Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
Group II: PlaceboPlacebo Group1 Intervention
Participants will be randomized to receive placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ASC10
2022
Completed Phase 1
~80
Find a Location
Who is running the clinical trial?
Ascletis Pharmaceuticals Co., Ltd.Lead Sponsor
28 Previous Clinical Trials
2,593 Total Patients Enrolled
5 Trials studying COVID-19
171 Patients Enrolled for COVID-19
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have an allergy or medical condition that prevents you from taking any of the study treatments.You have a medical condition that increases your risk of severe or critical illness from COVID-19.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo
- Group 2: ASC10
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has ASC10 acquired clearance from the United States Food and Drug Administration?
"As ASC10 is in its initial trial phase, there is limited evidence of safety and efficacy so it has been assigned a rating of 1."
Answered by AI
Is this trial actively recruiting new participants?
"The clinical trial in question, which was posted on the 28th of November 2022 and updated lastly on the same date, is not accepting new participants. Despite this setback, 967 other medical studies are actively recruiting patients at this time."
Answered by AI
Share this study with friends
Copy Link
Messenger